Nakano A, Tamura M, Hatori M, Hasegawa A, Suzuki T, Murata K
Kokyu To Junkan. 1989 Oct;37(10):1097-101.
Bunazosin hydrochloride was administrated in 3-mg oral doses to the 10 patients (6 males and 4 females, average 49.9 years) with dilated cardiomyopathy (DCM) of class II in the NYHA functional classification. Then we observed the changes in their hemodynamics at rest, chest X-ray, echocardiography, humoral factors and symptom-limited exercise tolerance with treadmill testing before treatment and 4 and 8 weeks after administration. All but the left ventricular end-diastolic diameter after 8 weeks were unchanged. Of the humoral factors, only aldosterone decreased significantly during the treatment. On the other hand, the duration of symptom-limited exercise was prolonged significantly, and for a given exercise load, a reduction of heart rate and systolic blood pressure as well as a drop in the PRP occurred at 8 weeks after administration. Therefore, bunazosin appears to improve cardiac function and exercise tolerance in the patients with DCM, at dosages which do not affect hemodynamics at rest.
对10例纽约心脏病协会（NYHA）心功能分级为II级的扩张型心肌病（DCM）患者（6例男性，4例女性，平均年龄49.9岁）口服3毫克盐酸布那唑嗪。然后，我们观察了他们在治疗前以及给药后4周和8周时静息状态下的血流动力学变化、胸部X线、超声心动图、体液因子以及症状限制运动耐量（通过跑步机测试）。除了给药8周后的左心室舒张末期直径外，其他指标均无变化。在体液因子方面，治疗期间只有醛固酮显著降低。另一方面，症状限制运动的持续时间显著延长，并且在给药8周后，对于给定的运动负荷，心率、收缩压降低，射血前期（PRP）下降。因此，布那唑嗪似乎能改善DCM患者的心脏功能和运动耐量，且所用剂量不影响静息状态下的血流动力学。
